



Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

Store at -20C
#2286

LEF1 (C18A7) Rabbit mAb

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 25-58	Source/Isotype: Rabbit IgG	UniProt ID: #Q9UJU2	Entrez-Gene Id: 51176
-------------------------------	-----------------------------	-----------------------------------	---------------------------	--------------------------------------	-------------------------------	---------------------------------

Product Usage Information

Application

Western Blotting
Immunoprecipitation

Dilution

1:1000
1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

LEF1 (C18A7) Rabbit mAb detects endogenous level of total LEF1 proteins, including the dominant negative forms due to the usage of alternative promoter.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val282 of human LEF1.

Background

LEF1 and TCF are members of the high mobility group (HMG) DNA-binding protein family of transcription factors that consists of the following: Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1/TCF7), TCF3/TCF7L1, and TCF4/TCF7L2 (1). LEF1 and TCF1/TCF7 were originally identified as important factors that regulate early lymphoid development (2) and act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers, including colon cancer (4,5).

LEF1 has several isoforms due to alternative splicing. LEF1 also has an alternative promoter that is preferentially active in lymphocytes. The isoforms generated by this alternative promoter have no amino-terminal β-catenin binding domain, therefore, they may function in a dominant negative manner (6-8).

Background References

1. Waterman, M.L. (2004) *Cancer Metastasis Rev* 23, 41-52.
2. Schilham, M.W. and Clevers, H. (1998) *Semin Immunol* 10, 127-32.
3. Brantjes, H. et al. (2002) *Biol Chem* 383, 255-61.
4. Reya, T. and Clevers, H. (2005) *Nature* 434, 843-50.
5. Logan, C.Y. and Nusse, R. (2004) *Annu Rev Cell Dev Biol* 20, 781-810.
6. Hovanes, K. et al. (2000) *Nucleic Acids Res* 28, 1994-2003.
7. Hovanes, K. et al. (2001) *Nat Genet* 28, 53-7.
8. Kobiela, A. et al. (2001) *Acta Biochim Pol* 48, 221-6.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.